目的：探讨EB病毒Rta蛋白IgG抗体在鼻咽癌诊断中的临床价值。方法采用间接ELISA法检测612例临床样本中EB病毒Rta-IgG含量，同时对试剂盒的分析性能进行评估。结果267例鼻咽癌样本的EB病毒Rta-IgG抗体浓度为（77.64±3.205）U/ml，检测灵敏度为94.7％（214/226），特异度为86.3％（333/386），正确率为89.4％（547/612）；255例健康体检血样抗体浓度为（8.31±0.745）U/ml；20例肝癌样本抗体浓度为（7.14±1.111） U/ml；30例肝炎样本抗体浓度为（7.40±0.581） U/ml；20例自身免疫病样本抗体浓度为（13.97±6.943）U/ml；20例鼻咽息肉样本抗体浓度为（12.58±6.197）U/ml。各组EB病毒Rta-IgG含量比较差异有统计学意义（ P＜0.05）。结论 EB病毒Rta-IgG定量检测试剂盒用于鼻咽癌诊断具有较高的临床价值，为进一步研究鼻咽癌患者治疗效果与患者血清中EB病毒Rta-IgG的含量的关系奠定了基础。%Objective To investigate the clinical value of Epstein-Barr virus ( EBV) Rta/IgG in the diagno-sis of nasopharyngeal carcinoma ( NPC) .Methods Sera from 612 clinical samples were measured for the Rta-IgG by an indirect enzyme-linked immunosorbent assay .In the present study , we also evaluated the performance of the Rta-IgG ELISA kits.Results The mean value of Rta-IgG concentration in 267 NPC patients was (77.64 ±3.205)U/ml with a sensitivity of 94.7%( 214/226 ) and specificity of 86.3%( 333/386 ) and accuracy of 89.4%( 547/612 ) . The mean value of Rta-IgG concentration in 255 healthy volunteers ,20 hepatocellular carcinoma patients ,30 hepatitis patients,20 patients with autoimmune disease and 20 patients with nasopharyngeal polyp were (8.31 ±0.745)U/ml, (7.14 ±1.111)U/ml, (7.40 ±0.581)U/ml, (13.97 ±6.943)U/ml and (12.58 ±6.197)U/ml, respectively. There were significant difference between NPC group and other groups .Conclusion Our results suggest that the EBV Rta/IgG ELISA kit is suitable for the clinical diagnosis of NPC .It also provides a basis for further study on the rela-tionship between the therapeutic effect and serum EBV Rta-IgG content in NPC patients .
展开▼
